Home Tags ASCO

Tag: ASCO

Clinical Phase I Data for ASG-15ME and Enfortumab Vedotin (ASG-22ME) Indicates...

Clinical data for ASG-15ME and Enfortumab vedotin, also known as ASG-22ME and ASG-22M6E,  presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting held June...
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

AbbVie Demonstrates Progress in Oncology Research at ASCO 2016

Chemotherapy remains the standard of care in the treatment of many types of cancer. However, one of the problems with chemotherapeutics is that it...

ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...

Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...

ADAPT Study Shows Promising Results in the Treatment of Patients with...

Results from the German phase II ADAPT study (WSG-ADAPT), showed that neoadjuvant ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech/Roche) is effective in the treatment of HER2-positive,...

ASCO 2015: Advancing Antibody-drug Conjugates in Difficult-to-treat Cancers

With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...

Brentuximab Vedotin Data from the AETHERA Post-Transplant Consolidation Setting Presented at...

Data from brentuximab vedotin (Adcetris®; Seattle Genetics) in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma...

Labetuzumab Govitecan is Active in Relapsed Metastatic Colorectal Cancer

An interim analysis of a mid-stage clinical study showed that labetuzumab govitecan, also known as  (IMMU-130), a novel antibody-drug conjugates or ADC being developed by...

What to Expect at ASCO 2015?

The 51st ASCO - the Annual Meeting of the American Society of Clinical Oncology, which will take place in the McCormick Place Convention Center in Chicago, Illinois, May 29 – June 2, 2015 is expected attract more than 30,000 oncology professionals from around the world.
ESMO 2014 Congress - Madrid, Spain

Initial Phase I Trial Results of anti-EGFR drug ABT-414 in the...

With a median survival between 1 and 2 years and no long-term curative treatments, the management of patients with Glioblastoma Multiforme (GBM), the most common and most aggressive type of malignant primary brain tumor, remains challenging.

SAR3419 Achieved Objective Responses Well Above Study Threshold and was Found...

A novel anticancer therapeutic called coltuximab ravtansine (CoR; SAR3419; Sanofi) shows favorable results in the Phase II STARLYTE trial in diffuse large B-cell lymphoma (DLBCL). SAR3419 is a humanized CD19 mAb linked to DM4, a maytansine analog, developed by ImmunoGen.